Vifor Pharma AG logo

VIFN - Vifor Pharma AG Share Price

CHF133.65 0.1  0.0%

Last Trade - 1:32pm

Large Cap
Market Cap £6.81bn
Enterprise Value £7.07bn
Revenue £1.34bn
Position in Universe 138th / 1048
Unlock VIFN Revenue
Relative Strength (%)
1m +4.81%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -15.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
3,792 1,167 1,292 1,585 1,877 1,706 1,895 2,081 -14.8%
+7.2 -51.4 -76.8 +346.3 +4.3 +6.9 +49.2 +26.4
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, ViforPharma AG revenues decreased 9% to SF1.71B. Net incomeapplicable to common stockholders excluding extraordinaryitems decreased 13% to SF138.7M. Revenues reflect Americasegment decrease of 4% to SF991.8M. Net income alsoreflects Research and development increase of 10% to SF250M(expense), Net foreign exchange differences increase fromSF13.5M to SF31.6M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


VIFN Revenue Unlock VIFN Revenue

Net Income

VIFN Net Income Unlock VIFN Revenue

Normalised EPS

VIFN Normalised EPS Unlock VIFN Revenue

PE Ratio Range

VIFN PE Ratio Range Unlock VIFN Revenue

Dividend Yield Range

VIFN Dividend Yield Range Unlock VIFN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
VIFN EPS Forecasts Unlock VIFN Revenue
Profile Summary

Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company's portfolio of iron deficiency treatments includes intravenous products, Ferinject and Venofer, and oral product, Maltofer, among others. Its portfolio of renal pharmaceuticals includes products for anaemia management, such as Mircera, mineral and bone management, such as Velphoro, Rayaldee and Osvaren, and cardio-renal management, such as patiromer (in the United States sold under the brand Veltassa). The Company also conducts research in the area of infectious and rare diseases, partnering with other biopharmaceutical companies. The Company has production sites in Switzerland and Portugal as well as a network of affiliates and partners around the world.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated January 6, 1933
Public Since February 25, 2003
No. of Shareholders: n/a
No. of Employees: 2,600
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Euromid ,
Exchange SIX Swiss Exchange
Shares in Issue 64,855,162
Free Float (0.0%)
Eligible for
VIFN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for VIFN
Upcoming Events for VIFN
Thursday 6th May, 2021
Vifor Pharma AG Annual Shareholders Meeting
Monday 10th May, 2021
Dividend For VIFN.S - 2.0000 CHF
Wednesday 26th May, 2021
Vifor Pharma AG at Erste Group CEE Innovation Conference (Virtual)
Wednesday 2nd June, 2021
Vifor Pharma AG at Stifel Swiss Equities Conference (Virtual)
Thursday 10th June, 2021
Vifor Pharma AG at Goldman Sachs European Financial Conference
Wednesday 16th June, 2021
Vifor Pharma AG at Deutsche Bank dbAccess Berlin Conference (Virtual)
Thursday 17th June, 2021
Vifor Pharma AG at JPMorgan European Healthcare Conference (Virtual)
Thursday 5th August, 2021
Half Year 2021 Vifor Pharma AG Earnings Release
Frequently Asked Questions for Vifor Pharma AG
What is the Vifor Pharma AG share price?

As of 1:32pm, shares in Vifor Pharma AG are trading at CHF133.65, giving the company a market capitalisation of £6.81bn. This share price information is delayed by 15 minutes.

How has the Vifor Pharma AG share price performed this year?

Shares in Vifor Pharma AG are currently trading at CHF133.65 and the price has moved by -5.05% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Vifor Pharma AG price has moved by -26.42% over the past year.

What are the analyst and broker recommendations for Vifor Pharma AG?

Of the analysts with advisory recommendations for Vifor Pharma AG, there are there are currently 2 "buy" , 9 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Vifor Pharma AG is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Vifor Pharma AG next release its financial results?

Vifor Pharma AG is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Vifor Pharma AG dividend yield?

The Vifor Pharma AG dividend yield is 1.5% based on the trailing twelve month period.

Does Vifor Pharma AG pay a dividend?

Last year, Vifor Pharma AG paid a total dividend of 2, and it currently has a trailing dividend yield of 1.5%. Looking ahead, shares in Vifor Pharma AG are due to go ex-dividend on 2021-05-10 and the next dividend pay date is 2021-05-12.

When does Vifor Pharma AG next pay dividends?

Vifor Pharma AG are due to go ex-dividend on 2021-05-10 and the next dividend pay date is 2021-05-12. The historic dividend yield on Vifor Pharma AG shares is currently 1.5%.

How do I buy Vifor Pharma AG shares?

To buy shares in Vifor Pharma AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Vifor Pharma AG?

Shares in Vifor Pharma AG are currently trading at CHF133.65, giving the company a market capitalisation of £6.81bn.

Where are Vifor Pharma AG shares listed? Where are Vifor Pharma AG shares listed?

Here are the trading details for Vifor Pharma AG:

Country of listing: Switzerland
Exchange: SWX
Ticker Symbol: VIFN
What kind of share is Vifor Pharma AG?

Based on an overall assessment of its quality, value and momentum, Vifor Pharma AG is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Vifor Pharma AG share price forecast 2021?

Shares in Vifor Pharma AG are currently priced at CHF133.65. At that level they are trading at 1.29% discount to the analyst consensus target price of 0.00.

Analysts covering Vifor Pharma AG currently have a consensus Earnings Per Share (EPS) forecast of 3.901 for the next financial year.

How can I tell whether the Vifor Pharma AG share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vifor Pharma AG. Over the past six months, the relative strength of its shares against the market has been -7.6%. At the current price of CHF133.65, shares in Vifor Pharma AG are trading at 4.75% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Vifor Pharma AG PE Ratio?

The Vifor Pharma AG PE ratio based on its reported earnings over the past 12 months is 51.1. The shares are currently trading at CHF133.65.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Vifor Pharma AG?

Vifor Pharma AG's management team is headed by:

Jacques Theurillat - NEC
Michel Burnier - IND
Romeo Cerutti - NVC
Stefan Schulze - CEO
Colin Bond - CFO
Michael Puri - CHO
Christoph Springer - EXB
Sue Mahony - IND
Klaus Jensen - EXB
Barbara Angehrn - EXB
Lee Heeson - EXB
Gilbert Achermann - IND
Gregory Oakes - EVP
Andreas Walde - SEC
Who are the major shareholders of Vifor Pharma AG?

Here are the top five shareholders of Vifor Pharma AG based on the size of their shareholding:

Ebner (Martin & Rosmarie) Individual Investor
Percentage owned: 20.38% (13.3m shares)
BNP Paribas Asset Management France SAS Investment Advisor/Hedge Fund
Percentage owned: 8.81% (5.73m shares)
Stoffel (Remo und Manuela) Individual Investor
Percentage owned: 7.1% (4.61m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.7% (3.06m shares)
Alecta pensionsförsäkring, ömsesidigt Investment Advisor
Percentage owned: 3.23% (2.10m shares)
Similar to VIFN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.